The treatment of non-small-cell lung carcinoma (NSCLC) has changed significantly in recent years, beginning with the discovery of oncogenic mutations as a molecular pathway responsible for some lung tumors, mainly not tobacco-related, for which anti-target therapies with excellent anti-tumor efficacy results have been developed. During the last few years, efforts have focused on the introduction of immunotherapy in earlier stages as neoadjuvant treatment for potentially resectable tumors and in an adjuvant setting, with some very promising results. With regard to earlier stages, consolidation immunotherapy after chemoradiation has also changed the paradigm of unresectable NSCLC, with marked benefits in terms of disease-free and overall survival. Initial successful results came from an improvement in overall survival for pretreated patients, and immunotherapy subsequently moved to a first-line palliative setting as monotherapy, in combination with chemotherapy or as double-checkpoint inhibition. The most widely used immunotherapy strategy in clinical practice is currently PD-1 and CTLA-4 immune checkpoint inhibition-based immunotherapy. Since 2015, immunotherapy has been changing the paradigm of NSCLC treatment in different settings and has contributed to improve the quality of life of these patients. Visit for more information.The treatment of non-small-cell lung carcinoma (NSCLC) has changed markedly in recent years as a result of two major treatment milestones: Targeted therapy and immunotherapy. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies.
#Keynote 189 overall survival update trial
The conference will cover a wide range ofdisciplines and unveil several research studies and clinical trial results. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries.
#Keynote 189 overall survival update plus
“Pembrolizumab plus chemotherapy had a similar OS benefit in the TMB-high and low subgroups.” “Tumor mutational burden was not significantly associated with efficacy of pembrolizumab plus chemotherapy or placebo plus chemotherapy as first-line therapy for metastatic nonsquamous NSCLC,”said Dr. Pembrolizumab plus chemotherapy improved overall survival, progression-free survival and objective response rate. TMB as a continuous variable was not significantly associated with overall survival, progression-free survival or objective response rate for pembrolizumab plus chemotherapy or placebo plus chemotherapy. Baseline characteristics and outcomes were generally similar in the TMB-evaluable and total populations. Of the 616 patients enrolled, 293 (48.3%) had evaluable TMB data: 207 for pembrolizumab plus chemotherapy, 86 for placebo plus chemotherapy. The clinical utility of TMB on outcomes was assessed using prespecified TMB cut points of 175 and 150 Mut/. TMB was determined by whole-exome sequencing of tumor and matched normal DNA. Garassino and her colleagues randomized 616 patients 2:1 to pembrolizumab plus chemotherapy or placebo plus chemotherapy.
TMB, in concert with PD-L1 expression, has been demonstrated to be a useful biomarker across some cancer types. Tumor mutational burden is a measurement of mutations carried by tumor cells and is a predictive biomarker being studied to evaluate its association with response to immunotherapy. Garassino presented this new data today at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer. Garassino from theFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Barcelona- Tumor mutational burden was not significantly associated with efficacy of pembrolizumab plus chemotherapy or placebo plus chemotherapy as first-line therapy for metastatic nonsquamous non-small cell lung cancer, according to research reported today by Dr.
0 kommentar(er)
